Skip to content

Study · Case report or series · n = 3 · 2020

5 results

A Case Study of L-Carnosine for Patient-Reported Outcomes and Brain Metabolism in Multiple Sclerosis

Ostojic S, Zanini D, Jezdimirovic T, Stajer V, Ostojic J, Maksimovic N

Current developments in nutrition29 May 2020

PMCIDPMC7258284 (opens in a new tab)PepBankPUB-98281585
Read at sourceSource pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In patients with multiple sclerosis, numbness scores decreased after L‑carnosine in all cases.

    In plain wordsIn patients with multiple sclerosis, numbness scores decreased after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    DecreaseNumbness score
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    The Visual Analog Scale scores for numbness, weakness, pain, and depression decreased in all MS patients at post-administration.
    2 context sentences
    Summary · context
    Two women (aged 37 and 48) and a man (age 48 years) who fulfilled the 2017 McDonald criteria for MS diagnosis, and were free of other major chronic diseases or acute disorders were recruited for this case study.
    Summary · context
    L-carnosine (2 g/day) was administered orally during 8 weeks in all MS patients.
  2. 02HumanCase report or seriesEfficacy outcome

    In patients with multiple sclerosis, weakness scores decreased after L‑carnosine in all cases.

    In plain wordsIn patients with multiple sclerosis, weakness scores decreased after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    DecreaseWeakness score
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    The Visual Analog Scale scores for numbness, weakness, pain, and depression decreased in all MS patients at post-administration.
    2 context sentences
    Summary · context
    Two women (aged 37 and 48) and a man (age 48 years) who fulfilled the 2017 McDonald criteria for MS diagnosis, and were free of other major chronic diseases or acute disorders were recruited for this case study.
    Summary · context
    L-carnosine (2 g/day) was administered orally during 8 weeks in all MS patients.
  3. 03HumanCase report or seriesEfficacy outcome

    In patients with multiple sclerosis, pain scores decreased after L‑carnosine in all cases.

    In plain wordsIn patients with multiple sclerosis, pain scores decreased after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    DecreasePain score
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    The Visual Analog Scale scores for numbness, weakness, pain, and depression decreased in all MS patients at post-administration.
    2 context sentences
    Summary · context
    Two women (aged 37 and 48) and a man (age 48 years) who fulfilled the 2017 McDonald criteria for MS diagnosis, and were free of other major chronic diseases or acute disorders were recruited for this case study.
    Summary · context
    L-carnosine (2 g/day) was administered orally during 8 weeks in all MS patients.
  4. 04HumanCase report or seriesEfficacy outcome

    In patients with multiple sclerosis, depression scores decreased after L‑carnosine in all cases.

    In plain wordsIn patients with multiple sclerosis, depression scores decreased after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    DecreaseDepression score
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    The Visual Analog Scale scores for numbness, weakness, pain, and depression decreased in all MS patients at post-administration.
    2 context sentences
    Summary · context
    Two women (aged 37 and 48) and a man (age 48 years) who fulfilled the 2017 McDonald criteria for MS diagnosis, and were free of other major chronic diseases or acute disorders were recruited for this case study.
    Summary · context
    L-carnosine (2 g/day) was administered orally during 8 weeks in all MS patients.
  5. 05HumanCase report or seriesActivity measurement

    In patients with multiple sclerosis, brain glutamate decreased by 22.6% on average after L‑carnosine.

    In plain wordsIn patients with multiple sclerosis, brain glutamate decreased after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    DecreaseBrain glutamate
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Metabolic pathways and metabolomics · Nervous system and cognition
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Measurements

    brain glutamate decrease
    22.6%
    average across all cases

    Source sentences

    Summary
    Single-voxel 1.5 T MRS revealed an increased brain choline-contained compounds (18.9% on average), total creatine (21.2%), and myo-inositol levels (12.3%) in girus cinguli at 8-week follow; this was accompanied by a drop in brain glutamate for 22.6% on average.
    2 context sentences
    Summary · context
    Two women (aged 37 and 48) and a man (age 48 years) who fulfilled the 2017 McDonald criteria for MS diagnosis, and were free of other major chronic diseases or acute disorders were recruited for this case study.
    Summary · context
    L-carnosine (2 g/day) was administered orally during 8 weeks in all MS patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.